Psoriasis Club
  • Forum
  • Home
  • Portal
  • Member List
  • Psoriasis Score
  • PQOLS
  • What is psoriasis
  • Search
  • Help
Hello Guest, Welcome To The Psoriasis Club Forum. We are a self funded friendly group of people who understand.
Never be alone with psoriasis, come and join us. (Members have more privileges)
wave
Login Register
Login
Username:
Password:
Lost Password?
 
Psoriasis Club › HealthHealth Boards › Psoriasis In The News v
« Previous 1 2 3 4 5 6 … 49 Next »

Ilumya / Ilumetri efficacy and safety in psoriatic arthritis

Threaded Mode
Ilumya / Ilumetri efficacy and safety in psoriatic arthritis
Fred Offline
I Wanted To Change the World But Got Up Far Too Late.
Moderator
Posts: 56,465
Threads: 3,540
Joined: Aug 2011
Gender: Male
Location: France
Psoriasis Score: 2
Psoriatic Arthritis Score: 2
PQOLS: 2
Treatment: Bimzelx / Coconut Oil
#1
News  Thu-09-09-2021, 19:53 PM
This study looked at the efficacy and safety of the anti-interleukin-23p19 monoclonal antibody Ilumya / Ilumetri (tildrakizumab) in patients with psoriatic arthritis (PsA)

Quote:
Objectives:
To evaluate efficacy and safety of the anti-interleukin-23p19 monoclonal antibody tildrakizumab in patients with psoriatic arthritis (PsA).

Methods:
In this randomised, double-blind, placebo-controlled, phase IIb study, patients with active PsA were randomised 1:1:1:1:1 to tildrakizumab 200 mg every 4 weeks (Q4W); tildrakizumab 200, 100 or 20 mg Q12W; or placebo Q4W. Patients receiving tildrakizumab 20 mg or placebo switched to tildrakizumab 200 mg Q12W at W24; treatment continued to W52. The primary efficacy endpoint was proportion of patients with ACR20 response (≥20% improvement by American College of Rheumatology criteria) at W24. Secondary efficacy endpoints were assessed without adjustment for multiplicity. Safety was evaluated from treatment-emergent adverse events (TEAEs).

Results:
391/500 patients screened were randomised and treated. At W24, 71.4%–79.5% of tildrakizumab-treated versus 50.6% of placebo-treated patients achieved ACR20 (all p<0.01). Patients receiving tildrakizumab versus placebo generally achieved higher rates of ACR50, Disease Activity Score in 28 joints with C reactive protein <3.2, minimal disease activity and 75%/90%/100% improvement from baseline Psoriasis Area and Severity Index responses at W24 and through W52. Improvement in dactylitis and enthesitis was not observed; results were mixed for other outcomes. Responses in patients switched to tildrakizumab 200 mg at W24 were consistent with treatment from baseline. TEAEs and serious TEAEs occurred in 64.5% and 3.3%, respectively, of all patients through W52 and were comparable among treatment arms.

Conclusions:
Tildrakizumab treatment significantly improved joint and skin manifestations of PsA other than dactylitis and enthesitis. Treatment was generally well tolerated through W52.

Source: bmj.com funding unknown

Ilumetri / Ilumya (tildrakizumab)
Quote
« Next Oldest | Next Newest »


Possibly Related Threads…
Thread Author Replies Views Last Post
News Efficacy and safety of orismilast for psoriasis Fred 0 222 Fri-09-12-2022, 13:24 PM
Last Post: Fred
News Otezla (apremilast) quality of life, efficacy, and safety study Fred 1 497 Tue-01-11-2022, 03:14 AM
Last Post: mataribot
News Ilumetri / Ilumya 52 week Italian study Fred 2 503 Wed-28-09-2022, 03:09 AM
Last Post: mataribot
News Ilumetri / Ilumya real-world effectiveness and safety Fred 0 391 Wed-07-09-2022, 14:42 PM
Last Post: Fred
News Tremfya going after psoriatic arthritis Fred 12 5,510 Sun-14-08-2022, 19:08 PM
Last Post: Caroline



Users browsing this thread: 1 Guest(s)
    Contact us | Login | Register | Home | Cookies/GDPR | RSS Syndication | Portal | Types Of Psoriasis | Psoriasis Score | Members Only Boards
    Copyright © 2010 - 2023 Psoriasis Club All Rights Reserved | Founded May 2010 | Psoriasis Club Is Self Funded Without Sponsors Or Donations | Software by MyBB | Social
Linear Mode
Threaded Mode